Literature DB >> 29601102

Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome.

Aritz Lopategi1, Roger Flores-Costa1, Bibiana Rius1, Cristina López-Vicario1,2, José Alcaraz-Quiles1, Esther Titos1,2,3, Joan Clària1,2,3,4.   

Abstract

The prototypic proinflammatory cytokine IL-1β plays a central role in innate immunity and inflammatory disorders. The formation of mature IL-1β from an inactive pro-IL-1β precursor is produced via nonconventional multiprotein complexes called the inflammasomes, of which the most common is the nucleotide-binding domain leucine-rich repeat-containing protein 3 (NLRP3) inflammasome composed by NLRP3, (ASC) apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (CARD), and caspase-1. Specialized proresolving mediators (SPMs) promote resolution of inflammation, which is an essential process to maintain host health. SPMs prevent excessive inflammation by terminating the inflammatory response and returning to tissue homeostasis without immunosupression. This study tested the hypothesis that modulation of the NLRP3 inflammasome in macrophages is one mechanism involved in the SPM-regulated processes during resolution. Our findings demonstrate that the SPM resolvin D2 (RvD2) suppressed the expression of pro-IL-1β and reduced the secretion of mature IL-1β in bone marrow-derived macrophages challenged with LPS+ATP (classical NLRP3 inflammasome model) or LPS+palmitate (lipotoxic model). Similar findings were observed in thioglycolate-elicited peritoneal macrophages, in which RvD2 remarkably reduced ASC oligomerization, inflammasome assembly, and caspase-1 activity. In vivo, in a self-resolving zymosan A-induced peritonitis model, RvD2 blocked the NLRP3 inflammasome leading to reduced release of IL-1β into the exudates, repression of osteopontin, and MCP-1 expression and induction of M2 markers of resolution (i.e., CD206 and arginase-1) in peritoneal macrophages. RvD2 inhibitory actions were receptor mediated and were abrogated by a selective GPR18 antagonist. Together, these findings support the hypothesis that SPMs have the ability to inhibit the priming and to expedite the deactivation of the NLRP3 inflammasome in macrophages during the resolution process. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  D-series resolvins; inflammation; innate immune cells; resolution

Mesh:

Substances:

Year:  2018        PMID: 29601102     DOI: 10.1002/JLB.3HI0517-206RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  27 in total

Review 1.  Endocannabinoid signaling pathways: beyond CB1R and CB2R.

Authors:  Roger Gregory Biringer
Journal:  J Cell Commun Signal       Date:  2021-05-12       Impact factor: 5.782

Review 2.  Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition.

Authors:  Mohan Satish; Devendra K Agrawal
Journal:  Transl Res       Date:  2019-08-12       Impact factor: 7.012

Review 3.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

Review 4.  Specialized pro-resolving mediator network: an update on production and actions.

Authors:  Nan Chiang; Charles N Serhan
Journal:  Essays Biochem       Date:  2020-09-23       Impact factor: 8.000

Review 5.  New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery.

Authors:  Julia Park; Christopher J Langmead; Darren M Riddy
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-20

Review 6.  Inflammation Resolution: Implications for Atherosclerosis.

Authors:  Amanda C Doran
Journal:  Circ Res       Date:  2022-01-07       Impact factor: 17.367

7.  Sex and puberty-related differences in metabolomic profiles associated with adiposity measures in youth with obesity.

Authors:  Christoph Saner; Brooke E Harcourt; Ahwan Pandey; Susan Ellul; Zoe McCallum; Kung-Ting Kao; Celia Twindyakirana; Anke Pons; Erin J Alexander; Richard Saffery; David P Burgner; Markus Juonala; Matthew A Sabin
Journal:  Metabolomics       Date:  2019-05-03       Impact factor: 4.290

8.  Cutting Edge: Human Vagus Produces Specialized Proresolving Mediators of Inflammation with Electrical Stimulation Reducing Proinflammatory Eicosanoids.

Authors:  Charles N Serhan; Xavier de la Rosa; Charlotte C Jouvene
Journal:  J Immunol       Date:  2018-10-24       Impact factor: 5.422

9.  Macrophage Responses to Environmental Stimuli During Homeostasis and Disease.

Authors:  Adil Rasheed; Katey J Rayner
Journal:  Endocr Rev       Date:  2021-07-16       Impact factor: 19.871

10.  Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation.

Authors:  Stefania Lamon-Fava; Jisun So; David Mischoulon; Thomas R Ziegler; Boadie W Dunlop; Becky Kinkead; Pamela J Schettler; Andrew A Nierenberg; Jennifer C Felger; Krishna Rao Maddipati; Maurizio Fava; Mark Hyman Rapaport
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-12-05       Impact factor: 4.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.